5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Australia Drug Delivery Devices Market is Segmented by Route of Administration (Injectable, Topical, Ocular and Others), Application and End User
2018 - 2026
The Australia Drug Delivery Devices Market is expected to register a CAGR of nearly 5.1% during the forecast period. The major factors driving the Australia Drug Delivery Devices Market are the rising prevalence of chronic diseases and technological advancements.
As drug delivery devices help in delivering the drugs which are beneficial for the targeted population to recover faster. In addition, a rising number of cancer, respiratory and diabetic patients in Australia will promote the adoption of drug delivery devices and drive the overall market. For instance, as per Australian Bureau of Statistics (ABS) 2017–18 National Health Survey, estimated that around 1.2 million Australians (4.9% of the total population) had diabetes in 2017–18.
In addition, as per the Australian Bureau of Statistics (ABS) 2017–18 National Health Survey, estimated that around 1.2 million (5.6%) Australian adults aged 18 years and over had 1 or more conditions related to the heart or vascular disease, including stroke in 2017–18. Thus, owing to the above-mentioned factors the market is expected to grow over the forecast period.
As per the scope, drug delivery devices or system are the tools which are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The Australia Drug Delivery Devices Market is segmented by route of administration, application, and end-user.
Report scope can be customized per your requirements. Click here.
Cancer is a major cause of illness in Australia and has a substantial social and economic impact on individuals, families, and the community. Cancer is a leading cause of death in Australia. In 2019, almost 50,000 deaths were caused due to cancer as per Cancer Council Australia. The government and many organizations have also taken initiatives to spread awareness regarding the diseases and available treatments which is expected to boost the market.
According to Globocan, in 2018, around 1,97, 876 new cancer cases were diagnosed, and 49,500 deaths were reported, in Australia. Thus, the rising burden of cancer and the initiatives to spread awareness regarding cancer treatment in the country is expected to drive market growth in the near future.
To understand key trends, Download Sample Report
The Australia Drug Delivery Devices Market is fragmented competitive and consists of several major players. Some of the companies which are currently dominating the market are Mylan N.V.,, GlaxoSmithKline Plc, Novartis AG, AbbVie Inc, Becton, Dickinson and Company, Novo Nordisk, Johnson & Johnson, Sanofi and Teva Pharmaceutical Industries Ltd.
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Technological Advancements
4.3 Market Restraints
4.3.1 Risk of Needlestick Injuries
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Route of Administration
5.1.4 Other Route of Administration
5.2 By Application
5.2.4 Infectious diseases
5.2.5 Other Applications
5.3 By End User
5.3.2 Ambulatory Surgical Centers
5.3.3 Other End Users
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Viatris Inc (Mylan N.V.)
6.1.2 Novartis AG
6.1.3 GlaxoSmithKline Plc
6.1.4 Becton, Dickinson and Company
6.1.5 AbbVie Inc
6.1.6 Novo Nordisk
6.1.7 Johnson & Johnson
6.1.8 Sanofi AG
6.1.9 Teva Pharmaceutical Industries Ltd
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments